Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgical Mesh | 20 | 2018 | 46 | 6.780 |
Why?
|
| Urinary Incontinence, Stress | 21 | 2019 | 64 | 6.220 |
Why?
|
| Pelvic Organ Prolapse | 13 | 2017 | 42 | 4.380 |
Why?
|
| Prostatic Hyperplasia | 16 | 2019 | 54 | 2.780 |
Why?
|
| Urinary Incontinence | 7 | 2018 | 45 | 2.420 |
Why?
|
| Uterine Prolapse | 7 | 2018 | 21 | 2.240 |
Why?
|
| Suburethral Slings | 5 | 2019 | 11 | 2.150 |
Why?
|
| Urinary Bladder, Overactive | 6 | 2018 | 14 | 2.020 |
Why?
|
| Urethra | 7 | 2019 | 100 | 1.840 |
Why?
|
| Urologic Diseases | 5 | 2014 | 28 | 1.630 |
Why?
|
| Biocompatible Materials | 7 | 2014 | 210 | 1.540 |
Why?
|
| Urologic Surgical Procedures | 7 | 2018 | 60 | 1.490 |
Why?
|
| Pelvic Floor | 7 | 2017 | 18 | 1.440 |
Why?
|
| Urology | 3 | 2014 | 30 | 1.420 |
Why?
|
| Humans | 87 | 2019 | 29220 | 1.270 |
Why?
|
| Polypropylenes | 4 | 2012 | 7 | 1.230 |
Why?
|
| Stents | 6 | 2015 | 171 | 1.110 |
Why?
|
| Regenerative Medicine | 3 | 2019 | 187 | 1.020 |
Why?
|
| Prostheses and Implants | 5 | 2018 | 41 | 1.020 |
Why?
|
| Ablation Techniques | 6 | 2019 | 24 | 1.010 |
Why?
|
| Vagina | 5 | 2018 | 49 | 1.000 |
Why?
|
| Female | 50 | 2019 | 18241 | 1.000 |
Why?
|
| Prosthesis Failure | 2 | 2015 | 43 | 0.970 |
Why?
|
| Urethral Obstruction | 4 | 2015 | 7 | 0.940 |
Why?
|
| Prostatectomy | 5 | 2019 | 79 | 0.900 |
Why?
|
| Algorithms | 4 | 2018 | 463 | 0.860 |
Why?
|
| Transurethral Resection of Prostate | 5 | 2019 | 8 | 0.830 |
Why?
|
| Urinary Catheterization | 3 | 2018 | 14 | 0.800 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 327 | 0.800 |
Why?
|
| Cystitis, Interstitial | 5 | 2019 | 37 | 0.770 |
Why?
|
| Urinary Bladder Diseases | 3 | 2017 | 18 | 0.750 |
Why?
|
| Internship and Residency | 3 | 2014 | 283 | 0.750 |
Why?
|
| Tissue Engineering | 2 | 2019 | 608 | 0.740 |
Why?
|
| Urinary Bladder | 7 | 2019 | 165 | 0.730 |
Why?
|
| Prostate | 5 | 2019 | 68 | 0.720 |
Why?
|
| Postoperative Complications | 10 | 2018 | 670 | 0.720 |
Why?
|
| Urodynamics | 7 | 2018 | 34 | 0.710 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2017 | 6 | 0.690 |
Why?
|
| Hydronephrosis | 2 | 2017 | 12 | 0.680 |
Why?
|
| Ureteral Diseases | 1 | 2017 | 7 | 0.640 |
Why?
|
| Prosthesis Design | 2 | 2015 | 87 | 0.600 |
Why?
|
| Treatment Outcome | 16 | 2019 | 3108 | 0.570 |
Why?
|
| Aged | 33 | 2019 | 9515 | 0.550 |
Why?
|
| Exercise Therapy | 2 | 2018 | 229 | 0.540 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2017 | 41 | 0.540 |
Why?
|
| Reconstructive Surgical Procedures | 3 | 2018 | 190 | 0.530 |
Why?
|
| Medical Device Recalls | 1 | 2015 | 2 | 0.520 |
Why?
|
| Public Opinion | 1 | 2014 | 17 | 0.500 |
Why?
|
| Device Removal | 2 | 2012 | 31 | 0.490 |
Why?
|
| Compensation and Redress | 1 | 2013 | 2 | 0.480 |
Why?
|
| Malpractice | 1 | 2013 | 20 | 0.470 |
Why?
|
| Male | 37 | 2019 | 17876 | 0.470 |
Why?
|
| Quality of Life | 6 | 2019 | 820 | 0.470 |
Why?
|
| Muscle Contraction | 2 | 2018 | 114 | 0.470 |
Why?
|
| Liability, Legal | 1 | 2013 | 28 | 0.470 |
Why?
|
| Water | 5 | 2019 | 50 | 0.460 |
Why?
|
| Foreign-Body Reaction | 1 | 2012 | 5 | 0.450 |
Why?
|
| Materials Testing | 1 | 2012 | 84 | 0.430 |
Why?
|
| Stroke | 2 | 2012 | 549 | 0.430 |
Why?
|
| Myoblasts | 3 | 2017 | 38 | 0.430 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 16 | 0.420 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 35 | 0.400 |
Why?
|
| Collagen | 4 | 2017 | 217 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2014 | 466 | 0.370 |
Why?
|
| Middle Aged | 28 | 2019 | 10872 | 0.370 |
Why?
|
| Muscarinic Antagonists | 1 | 2009 | 15 | 0.350 |
Why?
|
| Animals | 12 | 2019 | 7302 | 0.350 |
Why?
|
| Retrospective Studies | 11 | 2019 | 3122 | 0.340 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 3728 | 0.330 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 60 | 0.330 |
Why?
|
| Dietary Proteins | 1 | 2008 | 50 | 0.330 |
Why?
|
| Soybean Proteins | 1 | 2008 | 64 | 0.320 |
Why?
|
| Postoperative Hemorrhage | 2 | 2018 | 38 | 0.310 |
Why?
|
| Urethral Diseases | 2 | 2018 | 16 | 0.300 |
Why?
|
| Follow-Up Studies | 8 | 2015 | 2114 | 0.280 |
Why?
|
| Microwaves | 2 | 2008 | 8 | 0.270 |
Why?
|
| Pelvic Pain | 2 | 2017 | 18 | 0.270 |
Why?
|
| Adult | 16 | 2019 | 8468 | 0.270 |
Why?
|
| Forecasting | 2 | 2018 | 133 | 0.260 |
Why?
|
| Prevalence | 3 | 2017 | 907 | 0.250 |
Why?
|
| Diathermy | 1 | 2004 | 1 | 0.250 |
Why?
|
| Kidney Pelvis | 4 | 1992 | 21 | 0.240 |
Why?
|
| Ureteral Obstruction | 4 | 1992 | 29 | 0.240 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 441 | 0.240 |
Why?
|
| Peptides | 1 | 2004 | 118 | 0.230 |
Why?
|
| Urethral Stricture | 2 | 2017 | 29 | 0.210 |
Why?
|
| Risk Assessment | 2 | 2017 | 1313 | 0.200 |
Why?
|
| Erectile Dysfunction | 2 | 2018 | 48 | 0.190 |
Why?
|
| Chondrocytes | 1 | 2001 | 71 | 0.190 |
Why?
|
| Chemokine CXCL12 | 2 | 2018 | 25 | 0.180 |
Why?
|
| Incidence | 2 | 2014 | 1123 | 0.180 |
Why?
|
| Macaca fascicularis | 4 | 2018 | 389 | 0.180 |
Why?
|
| Polyneuropathies | 1 | 2019 | 10 | 0.170 |
Why?
|
| Hydrotherapy | 1 | 2019 | 3 | 0.170 |
Why?
|
| Fibromyalgia | 1 | 2019 | 24 | 0.170 |
Why?
|
| Anesthesia | 1 | 2019 | 65 | 0.170 |
Why?
|
| Hernia, Inguinal | 1 | 2018 | 2 | 0.170 |
Why?
|
| Pubic Symphysis Diastasis | 1 | 2018 | 3 | 0.170 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2010 | 65 | 0.160 |
Why?
|
| Time Factors | 6 | 2019 | 2003 | 0.160 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2018 | 8 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2018 | 31 | 0.160 |
Why?
|
| Electric Stimulation Therapy | 1 | 2018 | 18 | 0.160 |
Why?
|
| Patient Positioning | 1 | 2018 | 21 | 0.160 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 17 | 0.160 |
Why?
|
| Electrocoagulation | 1 | 2018 | 12 | 0.160 |
Why?
|
| Aging | 3 | 2017 | 881 | 0.160 |
Why?
|
| Adenoma | 1 | 2018 | 35 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2018 | 91 | 0.160 |
Why?
|
| Organ Size | 4 | 2019 | 196 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2017 | 64 | 0.160 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 32 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 37 | 0.150 |
Why?
|
| Elastin | 2 | 2014 | 14 | 0.150 |
Why?
|
| Anesthetics | 2 | 2019 | 19 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2018 | 92 | 0.150 |
Why?
|
| RNA | 2 | 2016 | 88 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 223 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 493 | 0.150 |
Why?
|
| Self Care | 1 | 2018 | 137 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2019 | 2027 | 0.150 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 208 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 74 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2017 | 333 | 0.140 |
Why?
|
| United States | 3 | 2014 | 3648 | 0.130 |
Why?
|
| Urination | 2 | 2008 | 15 | 0.130 |
Why?
|
| Risk Factors | 4 | 2017 | 3550 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 116 | 0.130 |
Why?
|
| Frail Elderly | 1 | 2015 | 65 | 0.130 |
Why?
|
| Laser Therapy | 1 | 2015 | 52 | 0.130 |
Why?
|
| Gene Expression | 1 | 2016 | 332 | 0.130 |
Why?
|
| Kidney Neoplasms | 3 | 2008 | 192 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 864 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 981 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 50 | 0.120 |
Why?
|
| Cystocele | 2 | 2017 | 4 | 0.110 |
Why?
|
| Internet | 1 | 2014 | 158 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2010 | 20 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 39 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2014 | 154 | 0.110 |
Why?
|
| Adenocarcinoma | 2 | 2008 | 301 | 0.100 |
Why?
|
| Extracellular Matrix | 2 | 2011 | 226 | 0.100 |
Why?
|
| Kidney Calculi | 3 | 1990 | 25 | 0.100 |
Why?
|
| Nephrostomy, Percutaneous | 3 | 1988 | 19 | 0.100 |
Why?
|
| Cadaver | 2 | 2016 | 143 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 481 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 40 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2011 | 190 | 0.090 |
Why?
|
| Regeneration | 1 | 2011 | 167 | 0.090 |
Why?
|
| Credentialing | 1 | 2009 | 8 | 0.090 |
Why?
|
| Benzofurans | 1 | 2009 | 5 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 2009 | 13 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 203 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 88 | 0.090 |
Why?
|
| Cystectomy | 1 | 2010 | 102 | 0.080 |
Why?
|
| Carbachol | 1 | 2008 | 7 | 0.080 |
Why?
|
| BCG Vaccine | 1 | 2008 | 7 | 0.080 |
Why?
|
| Phenylephrine | 1 | 2008 | 27 | 0.080 |
Why?
|
| Prolapse | 2 | 2005 | 7 | 0.080 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 40 | 0.080 |
Why?
|
| Probability | 1 | 2008 | 150 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2008 | 73 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 51 | 0.080 |
Why?
|
| Patient Selection | 1 | 2010 | 257 | 0.080 |
Why?
|
| Hematuria | 1 | 2008 | 7 | 0.080 |
Why?
|
| Reference Values | 1 | 2008 | 224 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2008 | 147 | 0.080 |
Why?
|
| Random Allocation | 1 | 2008 | 213 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2011 | 386 | 0.080 |
Why?
|
| Biological Products | 1 | 2009 | 66 | 0.080 |
Why?
|
| Robotics | 1 | 2009 | 122 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 179 | 0.080 |
Why?
|
| Solvents | 1 | 2007 | 4 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2008 | 79 | 0.080 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 2 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 533 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 519 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2018 | 504 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2018 | 267 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2007 | 56 | 0.070 |
Why?
|
| Primates | 2 | 2017 | 101 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 1079 | 0.070 |
Why?
|
| Fascia | 1 | 2005 | 9 | 0.070 |
Why?
|
| Nephrectomy | 1 | 2007 | 114 | 0.070 |
Why?
|
| Adolescent | 5 | 2019 | 3265 | 0.070 |
Why?
|
| Urinary Diversion | 1 | 1985 | 26 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2007 | 169 | 0.060 |
Why?
|
| Ethanol | 1 | 2007 | 185 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2004 | 4 | 0.060 |
Why?
|
| Collagen Type III | 1 | 2004 | 13 | 0.060 |
Why?
|
| Cross-Linking Reagents | 1 | 2004 | 16 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 298 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2004 | 39 | 0.060 |
Why?
|
| Ultrasonography | 2 | 1990 | 347 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2016 | 478 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2016 | 370 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 152 | 0.060 |
Why?
|
| Radiography | 4 | 1992 | 353 | 0.050 |
Why?
|
| Pelvis | 2 | 2018 | 61 | 0.050 |
Why?
|
| Hernia | 2 | 2017 | 12 | 0.050 |
Why?
|
| Cystoscopy | 2 | 2014 | 26 | 0.050 |
Why?
|
| Ear, External | 1 | 2001 | 8 | 0.050 |
Why?
|
| Ileal Diseases | 1 | 1980 | 3 | 0.050 |
Why?
|
| Urinary Bladder Fistula | 1 | 1980 | 3 | 0.050 |
Why?
|
| Sigmoid Diseases | 1 | 1980 | 5 | 0.050 |
Why?
|
| Intestinal Fistula | 1 | 1980 | 11 | 0.050 |
Why?
|
| Crohn Disease | 1 | 1980 | 25 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2004 | 423 | 0.050 |
Why?
|
| Young Adult | 2 | 2019 | 2413 | 0.050 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2018 | 4 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 2018 | 9 | 0.040 |
Why?
|
| Perineum | 1 | 2018 | 14 | 0.040 |
Why?
|
| Prostatism | 1 | 2018 | 3 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 13 | 0.040 |
Why?
|
| Ejaculation | 1 | 2018 | 2 | 0.040 |
Why?
|
| Lithotripsy | 2 | 1990 | 12 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 10 | 0.040 |
Why?
|
| Endosonography | 1 | 2018 | 56 | 0.040 |
Why?
|
| Compliance | 1 | 2017 | 12 | 0.040 |
Why?
|
| Pressure | 1 | 2017 | 54 | 0.040 |
Why?
|
| Length of Stay | 1 | 2018 | 294 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 73 | 0.040 |
Why?
|
| Chemokines | 1 | 2016 | 35 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2017 | 172 | 0.040 |
Why?
|
| Social Behavior | 1 | 2017 | 67 | 0.040 |
Why?
|
| Urine | 1 | 2017 | 59 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2016 | 104 | 0.030 |
Why?
|
| Color | 1 | 2015 | 13 | 0.030 |
Why?
|
| Recurrence | 2 | 2003 | 235 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 45 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 61 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 64 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 290 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 14 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 19 | 0.030 |
Why?
|
| Syndrome | 1 | 2014 | 66 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2003 | 142 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 241 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1219 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 629 | 0.030 |
Why?
|
| Kidney | 2 | 1987 | 486 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 9 | 0.030 |
Why?
|
| Urinary Bladder Calculi | 1 | 1991 | 3 | 0.020 |
Why?
|
| Child | 2 | 1988 | 2221 | 0.020 |
Why?
|
| Dilatation | 1 | 1990 | 9 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 1990 | 37 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 45 | 0.020 |
Why?
|
| Ureter | 1 | 1988 | 35 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 163 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 836 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 60 | 0.020 |
Why?
|
| Reoperation | 1 | 1988 | 203 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2007 | 13 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2009 | 307 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2007 | 72 | 0.020 |
Why?
|
| Intubation | 1 | 1985 | 8 | 0.020 |
Why?
|
| Urography | 1 | 1985 | 13 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1987 | 109 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 641 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1988 | 1168 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 6 | 0.020 |
Why?
|
| Scrotum | 1 | 1983 | 8 | 0.010 |
Why?
|
| Torsion Abnormality | 1 | 1983 | 7 | 0.010 |
Why?
|
| Abdomen | 1 | 2004 | 42 | 0.010 |
Why?
|
| Urethral Neoplasms | 1 | 2003 | 5 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 103 | 0.010 |
Why?
|
| Metaplasia | 1 | 2003 | 20 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 22 | 0.010 |
Why?
|
| Endoscopy | 1 | 2003 | 40 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 167 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 203 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 871 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 800 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 1981 | 1 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 860 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 1980 | 18 | 0.010 |
Why?
|
| Pregnancy | 1 | 1980 | 816 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1981 | 384 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1992 | 75 | 0.010 |
Why?
|
| Causality | 1 | 1991 | 39 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 39 | 0.010 |
Why?
|